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A huge retroperitoneal tumor with a right orbital mass was detected and proved to be an extragonadal nonseminomatous germ
cell tumor on biopsy. BEP chemotherapy caused some regression in orbital mass however no change in retroperitoneal tumor
size as well as serum tumor marker levels occurred. Herein, we present a rarely seen entity of extragonadal retroperitoneal
nonseminomatous germ cell tumor with synchronous orbital metastases and discuss its diagnosis and management.
Copyright © 2009 Ali Fuat Atmaca et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Extragonadal germ cell tumors (EGGCT) account for
approximately 2–5% of all germ cell tumors. They are mostly
seen in the mediastinum and retroperitoneum. However,
it can also be seen in less frequent locations such as
sacrococygeal region, pineal region, prostate, orbita, liver,
vagina, and gastrointestinal tract [1, 2].
These lesions may grow up to extensive dimensions
without any signiﬁcant symptoms. The diagnosis is usually
made in the third decade. Advanced local disease and distant
metastasesmightexistatthetimeofdiagnosisinthemajority
of patients [3].
2.CaseReport
A 31-year-old man complaining of bilateral lumber pain,
fatigue was diagnosed with right hydronephrosis on ultra-
sonography (US), and a double J stent was placed into the
right ureter at another hospital a month ago. He then was
referred to our institution for further evaluation. His past
medical history revealed bilateral nephrolithotomy in 1998
and right nephrolithotomy in 1999. Physical examination
of urogenital system was within normal limits including
the scrotal examination. On admission, there was proptosis
(eccentric)presentdisplacing his right eyeinfero-nasally.His
blood hemoglobulin and leukocyte counts were 7.81g/dL
and 21500, respectively. Blood chemistry was within nor-
mal limits except elevated urea (49mg/dL) and creatinine
(2.1mg/dL) levels. Serum tumor marker studies revealed
an increased beta-human chorionic gonadotropin (β HCG)
level (37.8mIU/mL) and an increased lactate dehydrogenase
(LDH) level (800IU/L). Serum alpha fetoprotein (AFP) level
was within normal limits.
Abdominal doppler US has shown multiple bilateral
renal stones, grade 2 ectasia in the left kidney and multiple
irregular iso-hyperechoic hypervascular solid lesions in the
right kidney. Additionally, scrotal US examination revealed
no abnormalities.
On computerized tomography scans, multiple heavily
contrast-stained conglomaralated necrotic lymphadenopa-
thies undiﬀerentiated from right kidney in paraaortic and
paracaval regions and destruction of L2 vertebral body were
observed (Figure 1(a)). On magnetic resonance imaging,
a contrast stained mass of 23 × 20 × 18mm in size
displacingsuperiorandlateralorbitalrectusmusclesandalso2 Advances in Urology
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Figure 1: (a) CT of the retroperitoneal mass. Note the vertebral body invasion (arrow). CT: Computerized tomography. (b) T1-weighted
MRI scans of the right orbital mass (arrow). MRI: Magnetic resonance imaging.
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Figure 2: (a) Microscopic appearance of tumor cells showing diﬀuse and strong positive immunohistochemical staining for alpha
fetoprotein. (b) Microscopic appearance of tumor cells showing diﬀuse and strong positive immunohistochemical staining for beta human
chorionic gonadotropin.
inﬁltrating into the frontal bone was seen in the right orbita
(Figure 1(b)).
Fine needle aspiration cytology from retroperitoneal
mass demonstrated a carcinoma associated with germ cell
tumor with positive staining for both AFP and β-HCG on
immunohistochemical evaluation (Figures 2(a) and 2(b)).
The diagnosis was made as primary nonseminomatous
extragonadal (retroperitoneal) germ cell tumor (EGGCT)
with orbital metastasis. Chemotherapy including cisplatin,
etoposide, and bleomycine (BEP) was administered. After
completion of ﬁrst course chemotherapy, symptoms sub-
sided with a signiﬁcant reduction in proptosis. However,
serum tumor marker levels did not change. Afterwards, a
very rapid progression of the disease has occurred following
initial regression of his symptoms. Dimensions of orbital
lesion increased signiﬁcantly with concomitant increase in
serum tumor marker levels including AFP and β-HCG.
Unfortunately, the patient died after the second course of
chemotherapy.
3. Discussion
EGGCTs are rarely seen tumors with speciﬁc biological and
clinical characteristics. Symptoms depend on the location of
the tumor such as presence of a palpable mass, abdominal
or back pain, dysphagia, and edema in the limbs when
the tumor is located in the retroperitoneum. Constitutional
symptoms such as fever and weight loss might accom-
pany the disease. The diagnosis is made histopathologically
when seminomatous and nonseminomatous elements of the
tumor are seen on biopsy. Tumor markers are also expected
to increase if nonseminomatous elements are present [1, 2].
In our patient, main symptoms were abdominal and low
back pain. Immunohistochemical evaluation of the biopsyAdvances in Urology 3
for AFP and HCG staining were positive therefore, the
patient was diagnosed as having extragonadal nonsemino-
matous germ cell tumor.
Metastases to other tissues depend on the localization
and histological type of the primary tumor [4]. Lung
metastasis rate has been reported to be 27% in mediastinal
nonseminomatous tumors whereas it has been reported
to be 49% in retroperitoneal tumors [4]. Additionally,
abdominal (34%), liver (25%), and cervical lymph node
(18%) metastases might also be present [4].
Scrotal US could easily diﬀerentiate a retroperitoneal
EGGCT from primary testicular tumor metastases without
routinely performing testicular biopsy for diﬀerential diag-
nosis [2].
The prognosis is excellent in cases with seminomatous
histology regardless of the localization of the EGGCT either
in mediastinum or in retroperitoneum. However, prognosis
of nonseminomatous EGGCT is worse than that of the
seminomatous variant. Five-year-survival rates have been
reported to be 45% for mediastinal and 62% for retroperi-
toneal nonseminomatous tumors [2, 4]. Unfortunately, the
majority of patients (80%) have nonseminomatous EGGCT
thus a poor prognosis which is independent of the primary
location of the nonseminomatous EGGCT [2, 4].
Management of patients with EGGCT is accomplished
according to the prognostic classiﬁcation of International
Germ Cell Cancer Collaboration Group [2]. Standard
cisplatinum-based chemotherapy plus additional secondary
surgery in half of the patients is the recommended
treatment strategy. Salvage chemotherapy including high-
dose chemotherapy does not have a signiﬁcant impact
on long-term survival. Regarding seminomatous tumors,
3 courses of BEP chemotherapy administration have been
suggested for patients with good prognosis, and 4 courses
of BEP chemotherapy have been recommended for patients
with moderate prognosis. In retroperitoneal nonseminatous
tumors, 3 and 4 courses of BEP chemotherapy regimen
should be administered to patients with good or moderate
and poor prognostic criteria, respectively. In patients with
mediastinal EGGCT, 4 courses of BEP chemotherapy are
suggested [2].
Secondary surgery is an integral part of the treatment
strategy in patients with EGGCT and is mandatory in cases
withresidualmass,whichistrueforabout50%ofthepatient
population [2].
We intended to treat our patient with 4 courses of BEP
chemotherapy; however, we were able to administer only two
courses. Unfortunately, we lost the patient despite partial
response with some regression in the diameter of the orbital
mass without any change in serum tumor marker levels.
In our case, a right orbital mass accompanying the
retroperitoneal tumor which we think was metastasis rather
than another primary focus regressed after the administra-
tionofﬁrstcourseofBEPchemotherapy.Becausethevolume
of the orbital tumor mass was smaller than the volume
of the retroperitoneal tumor, we think that orbital tumor
regressed to some degree while the retroperitoneal mass
remained unchanged without any change in serum tumor
marker levels.
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